细胞邻域决定抗CTLA-4后抗肿瘤T细胞浸润
基于II期SWOG S1616试验,分析抗PD-1原发耐药晚期黑色素瘤患者基线及治疗中活检。联合治疗应答者基线髓系细胞补体转录表达增高、内皮细胞干扰素通路及黑色素瘤细胞氧化磷酸化和脂质代谢增强;空间蛋白组学显示应答者治疗中活检有活化CD8 T细胞邻近黑色素瘤细胞的网络,或T细胞与髓系细胞共存,而进展者邻近浆细胞的T细胞浸润受损。
要点
- 抗PD-1原发耐药黑色素瘤联合抗CTLA-4应答者基线髓系补体及内皮干扰素通路表达增高。
- 应答者治疗中活检可见活化CD8 T细胞邻近黑色素瘤细胞或T细胞与髓系细胞共存网络。
- 进展者活检显示邻近浆细胞的T细胞浸润受损及浆细胞片状分布。
核心结论
- 联合抗CTLA-4逆转抗PD-1原发耐药与特定细胞邻域和转录组相关,进展者表现为浆细胞片状分布和T细胞浸润受损。
研究设计与样本
- II期SWOG S1616试验(NCT03033576)中抗PD-1/PD-L1原发耐药晚期黑色素瘤患者基线及治疗中活检的转录组和空间蛋白组学分析。
主要发现
- 联合治疗应答者基线髓系细胞补体转录表达增高,内皮细胞干扰素通路及黑色素瘤细胞氧化磷酸化和脂质代谢表达增高。
- 应答者治疗中活检部分显示活化CD8 T细胞邻近黑色素瘤细胞的网络,部分显示T细胞与髓系细胞共存,反映动态抗肿瘤反应不同时间点。
- 联合免疫治疗进展者活检显示邻近浆细胞的T细胞浸润受损。
临床怎么用
- 联合抗CTLA-4治疗前基线髓系补体及内皮干扰素通路表达可能提示应答,治疗中CD8 T细胞邻近黑色素瘤细胞或T-髓系细胞网络提示动态反应。
- 进展者活检邻近浆细胞的T细胞浸润受损及浆细胞片状分布,提示耐药微环境特征。
局限性
- 原文未报告样本量、统计阈值及置信区间等具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In the phase II trial SWOG S1616 (NCT03033576), patients with advanced melanoma with primary resistance to anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) therapies had improved outcomes with the combination of the anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) antibody ipilimumab with continued anti-PD-1 therapy with nivolumab, compared with ipilimumab alone. Baseline biopsies from patients responsive to combination therapy showed increased transcriptomic expression of complement by myeloid cells, interferon pathways by endothelial cells, and oxidative phosphorylation and lipid metabolism by melanoma cells. Using spatial proteomics, some on-therapy biopsies from patients responding to combination therapy exhibited networks of activated CD8 T cells near melanoma cells, whereas others had T and myeloid cells, reflecting different time points in a dynamic antitumor response. Conversely, biopsies from patients progressing on combination immunotherapy displayed impaired T-cell infiltration adjacent to plasma cells. Our results define cellular neighborhoods and transcriptomes in melanoma biopsies when reversing resistance to anti-PD-1 with the addition of anti-CTLA-4, and plasma cell sheets in nonresponding biopsies. SIGNIFICANCE: Patients with melanoma with primary resistance to anti-PD-1/PD-L1 therapies are treated with anti-PD-1 in combination with anti-CTLA-4. Melanoma biopsies responding to combination immunotherapy in the second line of care have distinct tumor microenvironments, with antitumor immune responses, compared with those that progress, which have impaired T-cell infiltration and plasma cell networks.
引用
- Campbell KM, Chen DG, Bustami ZE, et al. Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti-CTLA-4 in Melanoma with Primary Resistance to Anti-PD-1. Cancer Discov. 2026. PMID: 42013417. doi:10.1158/2159-8290.CD-25-1745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。